ARTICLE | Politics, Policy & Law

FDA scheduled Alzheimer’s drug coverage meeting with payers before aducanumab approval

July 1, 2021 1:42 AM UTC

FDA has commissioned Duke-Margolis Center to organize a private roundtable meeting in July with payers and other stakeholders to discuss challenges associated with covering and developing evidence for Alzheimer’s therapies such as aducanumab from Biogen and Eisai.

Payers were invited to the roundtable in the spring, before Aduhelm aducanumab’s approval. BioCentury spoke with three invited participants who did not want to be identified because the meeting is private. One participant told BioCentury that payers were surprised by the invitation, and some interpreted it as an early signal that FDA planned to approve Aduhelm. ...